Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2006-05-02
2006-05-02
Nickol, Gary B. (Department: 1642)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S006120, C436S064000
Reexamination Certificate
active
07037667
ABSTRACT:
Compositions for the diagnosis and therapy of prostate and colon cancer, derived from or based on a novel prostate-specific, androgen-related, cell membrane associated and secreted serine protease termed 20P1F12/TMPRSS2 are described. A full length cDNA comprising the entire coding sequence of the 20P1F12/TMPRSS2 gene (also designated 20P1F12-GTC1 herein) is provided (FIG.1). Among the compositions provided are antibodies that bind to 20P1F12/TMPRSS2 proteins and polypeptide fragments thereof, including antibodies labeled with a detectable marker or toxin or therapeutic composition. The invention also provides prognostic and diagnostic methods of examining a biological sample for evidence of disregulated cellular growth by comparing the status of 20P1F12/TMPRSS2 in the biological sample to the status of 20P1F12/TMPRSS2 in a corresponding normal sample, wherein alterations in the status of 20P1F12/TMPRSS2 in the biological sample are associated with disregulated cellular growth. The invention further provides various therapeutic compositions and strategies for treating prostate cancer, including particularly, 20P1F12/TMPRSS2 polypeptide and anti-20P1F12/TMPRSS2 antibody therapy methods and compositions, cancer vaccines, and small molecule therapy.
REFERENCES:
patent: 6043033 (2000-03-01), Bandman et al.
patent: 6166194 (2000-12-01), Wong et al.
patent: 6262245 (2001-07-01), Xu et al.
patent: 6294663 (2001-09-01), O'Brien et al.
patent: 6331427 (2001-12-01), Robison
patent: 6350448 (2002-02-01), Bandman et al.
patent: 1033401 (2000-09-01), None
patent: WO93/01309 (1993-01-01), None
patent: WO94/16083 (1994-07-01), None
patent: WO 98/37093 (1998-08-01), None
patent: WO 98/37418 (1998-08-01), None
patent: WO 99/62942 (1999-12-01), None
patent: WO 00/00605 (2000-01-01), None
patent: WO 00/04149 (2000-01-01), None
patent: WO 00/12758 (2000-03-01), None
patent: WO 00/18961 (2000-04-01), None
patent: WO 00/23111 (2000-04-01), None
patent: WO 00/55351 (2000-09-01), None
patent: WO 00/65067 (2000-11-01), None
patent: WO 01/22920 (2001-04-01), None
patent: WO 01/25272 (2001-04-01), None
patent: WO 01/34802 (2001-05-01), None
patent: WO 01/51633 (2001-07-01), None
patent: WO 01/57194 (2001-08-01), None
patent: WO 01/60860 (2001-08-01), None
patent: WO 01/73032 (2001-10-01), None
patent: WO 01/96538 (2001-12-01), None
patent: WO 02/04953 (2002-01-01), None
patent: WO 02/30268 (2002-04-01), None
Wong et al. (Sequence Comparison, USPTO Protein Database, Jun. 1998).
Afar D.E. et al. (2001). “Catalytic cleavage of the androgen-regulated TMPRSS2 protease results in its secretion by prostate and prostate cancer epithelia,”Cancer Res.61(4):1686-1692.
Hessels D. et al. (2004). “Applicability of biomarkers in the early diagnosis of prostate cancer,”Expert Rev. Mol. Diagn.4(4):513-526.
Lin B. et al. (1999). “Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2,”Cancer Res.59(17):4180-4184.
Paoloni-Giacobino A. et al. (2001). “Corrigenda,” Genomics 77(1-2):114. (Correction to Paoloni-Giacobino A. et al. (1997). “Cloning of the TMPRSS2 Gene, Which Encodes a Novel Serine Protease with Transmembrane, LDLRA, and SRCR Domains and Maps to 21q22.3,” Genomics, 44(3):309-320.)
Vaarala M.H. et al. (2001). “The TMPRSS2 gene encoding transmembrane serine protease is overexpressed in a majority of prostate cancer patients: detection of mutated TMPRSS2 form in a case of aggressive disease,”Int. J. Cancer94(5):705-710.
Wilson S. et al. (2004). “The membrane-anchored serine protease, TMPRSS2, activates PAR-2 in prostate cancer cells,”Biochem. J.Nov. 10, 2004 [Epub ahead of print], located at <http://www.ncbi.nlm.nih.gov/entrez/query.fogi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15537383> last visited on Dec. 1, 2004, 2 pages.
Paoloni-Giacobino, A., et al., “Cloning of the TMPRSS2 Gene, Which Encodes a Novel Serine Protease with Transmembrane, LDLRA and SRCR domains and maps to 21q22.3.”,Genomics,vol. 44(3), 1997, pp 309-320.
Database EMBL Nucleotide and Protein Sequences, Mar. 11, 1997, XP002132696, Hinxton, GB, Abstract.
Database EMBL Nucleotide and Protein Sequences, Mar. 20, 1997, XP002132697, Hinxton, GB, Abstract.
Fair, W.R. et al., “Prostate-Specific Membrane Antigen”,Prostate,vol. 32(2), 1997, XP-000870112, pp 140-148.
Young, Cyf et al., “Expression and Androgenic Regulation of Human Prostate-Specific Kallikreins”,Journal of Andrology,vol. 16 (2), Apr. 1995, XP-000867297, pp. 97-99.
Tanimoto, T. et al., “Hespin, a Cell Surface Serine Protease Identified in Hepatomoa Cells, is Overexpressed in Ovarian Cancer”,Cancer Research,vol. 57(14), Jul. 15, 1997, XP-000867297, pp. 2884-2887.
Yamamoto, M., “Raised Prostate-Specific Antigen in Adenocarcinoma of the Colon”,International Urology and Nephrology,vol. 29(2), 1997, XP-000889898 pp. 221-225.
Database EMBL Nucleotide and Protein Sequences, Nov. 16, 1998, XP-002132700, Hinxton, GB, Abstract.
Lin, B. et al., “Prostate-localized and Androgen-regulated Expression of the Membrane-bound Serine Protease TMPRSS21, ”Cancer Research,1999, pp. 4180-4184.
Hildmann, T. et al., “A Contiguous 3-Mb Sequence-Ready Map in the S3-MX Region on 21q22.2 Based on High-Throughput Nonisotopic Library Screenings,” Genome Research, 1999, 9:360-372.
Afar Daniel E. H.
Faris Mary
Hubert Rene S.
Jakobovits Aya
Leong Kahan
Agensys, Inc.
Morrison & Foerster / LLP
Nickol Gary B.
LandOfFree
Tumor antigen useful in diagnosis and therapy of prostate... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tumor antigen useful in diagnosis and therapy of prostate..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tumor antigen useful in diagnosis and therapy of prostate... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3574691